These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15133531)

  • 21. The in-vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results.
    Ruckdeschel G; Dalhoff A
    J Antimicrob Chemother; 1999 May; 43 Suppl B():25-9. PubMed ID: 10382872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presence of rifampicin in urine causes cross-reactivity with opiates using the KIMS method.
    Herrera Trevilla P; Ortiz Jimenez E; Tena T; Lora Tamayo C
    J Anal Toxicol; 1995; 19(3):200. PubMed ID: 7564301
    [No Abstract]   [Full Text] [Related]  

  • 23. Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis.
    Agalar C; Usubutun S; Turkyilmaz R
    Eur J Clin Microbiol Infect Dis; 1999 Aug; 18(8):535-8. PubMed ID: 10517189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Urinary excretion of rifampicin in kidney failure when administered alone or together with isoniazid].
    Titarenko OT; Vakhmistrova TI; Perova TL
    Antibiotiki; 1983 Sep; 28(9):698-702. PubMed ID: 6638984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite.
    Zheng HX; Huang Y; Frassetto LA; Benet LZ
    Clin Pharmacol Ther; 2009 Jan; 85(1):78-85. PubMed ID: 18843263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction between ciprofloxacin and rifampin.
    Temple ME; Nahata MC
    Ann Pharmacother; 1999; 33(7-8):868-70. PubMed ID: 10466918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug interactions -- the influence of rifampicin and clofazimine on the urinary excretion of DDS.
    Balakrishnan ; Seshadri PS
    Lepr India; 1981 Jan; 53(1):17-22. PubMed ID: 7218762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An in vitro investigation of the bioactivities of ciprofloxacin and the new fluoroquinolone agents clinafloxacin (CI-960) and PD 131628 against Mycobacterium tuberculosis in human macrophages.
    Van Rensburg CE; Jooné GK; Anderson R
    Chemotherapy; 1995; 41(4):234-8. PubMed ID: 7555202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin.
    Kelkar MS; Saraf AP; Bakhle DS; Nazare V; Ajay S; Hegde S; Lal HM; Cooverji ND; Bruzzese T
    Int J Clin Pharmacol Res; 1998; 18(3):137-43. PubMed ID: 9825270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose.
    Wagenlehner FM; Kinzig-Schippers M; Sörgel F; Weidner W; Naber KG
    Int J Antimicrob Agents; 2006 Dec; 28(6):551-9. PubMed ID: 17101261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
    Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
    Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of disseminated Mycobacterium szulgai infection with ciprofloxacin, rifampicin, and ethambutol.
    Fang CT; Chang SC; Luh KT; Chang YL; Hsueh PR; Hsieh WC
    J Infect; 1999 May; 38(3):195-7. PubMed ID: 10424803
    [No Abstract]   [Full Text] [Related]  

  • 33. In vitro susceptibility of Staphylococcus aureus isolated from blood to currently used antistaphylococcal drugs.
    Baiocchi P; Galiè M; Santini C; Carfagna P; Cassone M; Tarasi D; Venditti M
    J Chemother; 1998 Feb; 10(1):25-8. PubMed ID: 9531072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vitro activity of ciprofloxacin combined with either fusidic acid or rifampicin against Staphylococcus aureus.
    Røder BL; Gutschik E
    J Antimicrob Chemother; 1989 Mar; 23(3):347-52. PubMed ID: 2732119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study.
    Zhang W; Deng S; Chen XP; Zhou G; Xie HT; He FY; Cao D; Li YJ; Zhou HH
    Clin Ther; 2008 Jul; 30(7):1283-9. PubMed ID: 18691987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy.
    Heldman AW; Hartert TV; Ray SC; Daoud EG; Kowalski TE; Pompili VJ; Sisson SD; Tidmore WC; vom Eigen KA; Goodman SN; Lietman PS; Petty BG; Flexner C
    Am J Med; 1996 Jul; 101(1):68-76. PubMed ID: 8686718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects.
    Saima S; Furuie K; Yoshimoto H; Fukuda J; Hayashi T; Echizen H
    Br J Clin Pharmacol; 2002 Feb; 53(2):203-6. PubMed ID: 11851646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
    Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
    J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rifampin plus metronidazole for Clostridium difficile infection.
    Drekonja DM
    Infect Control Hosp Epidemiol; 2010 Nov; 31(11):1205; author reply 1205-6. PubMed ID: 20929305
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin.
    Potkar C; Gogtay N; Gokhale P; Kshirsagar NA; Ajay S; Cooverji ND; Bruzzese T
    Chemotherapy; 1999; 45(3):147-53. PubMed ID: 10224335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.